This review aims to provide comprehensive insight into the evolution of melanoma treatment, specifically discussing PD-1/PD-L1 inhibitors, T-VEC, mRNA vaccines, and tumor-infiltrating lymphocyte (TIL) therapy. This evidence concerns the gene PDCD1 and neoplasm.